Clinical Trials Browser

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Stomach Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

NCT04790708 2021-03-10

FENET-2016

Phase NA Unknown

250 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Phase NA Completed

39 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02657447 2019-01-10

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

AIDS-Related Complex, Immune System Diseases, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01915485 2016-09-07

Radiolabeled Molecules for Medullary Thyroid Cancer

Phase 4 Unknown

20 enrolled

Carcinoma, Medullary

NCT00860860 2012-03-19

PRIT2008

Phase 1 Completed

20 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

PSMA-DC

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

PSMACare

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

PSMAndARPI

GoTHAM

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

NETTER-P

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

RADIODOSE

NeoPSMA

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

STAMPEDE2

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

RIALTO

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

LuRM_ACC/2023

PSMA-ADJUVO

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

SEPTRALU

FENET-2016

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Radiolabeled Molecules for Medullary Thyroid Cancer

PRIT2008